NovaBay Pharmaceuticals, Inc.
NBY
$0.60
-$0.0436-6.77%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 2.31M | 2.42M | 2.39M | 2.62M |
| Total Other Revenue | -- | -3.00K | 17.00K | 13.00K | 7.00K |
| Total Revenue | -- | 2.31M | 2.44M | 2.40M | 2.63M |
| Cost of Revenue | -- | 807.00K | 848.00K | 808.00K | -- |
| Gross Profit | -- | 1.50M | 1.59M | 1.59M | -- |
| SG&A Expenses | 2.70M | 2.78M | 2.65M | 2.64M | 2.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.70M | 3.60M | 3.50M | 3.45M | 2.29M |
| Operating Income | -2.70M | -1.29M | -1.06M | -1.05M | -2.29M |
| Income Before Tax | -3.33M | -1.32M | -1.21M | -1.59M | -2.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.33M | -1.32M | -1.21M | -1.59M | -2.93M |
| Earnings from Discontinued Operations | 11.00M | 111.00K | -- | -- | -289.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.67M | -1.21M | -1.21M | -1.59M | -3.21M |
| EBIT | -2.70M | -1.29M | -1.06M | -1.05M | -2.29M |
| EBITDA | -2.70M | -1.28M | -1.05M | -1.04M | -2.28M |
| EPS Basic | 1.45 | -0.15 | -0.60 | -1.37 | -29.95 |
| Normalized Basic EPS | -0.32 | -0.10 | -0.20 | -0.81 | -15.57 |
| EPS Diluted | 1.45 | -0.15 | -0.60 | -1.37 | -29.95 |
| Normalized Diluted EPS | -0.32 | -0.10 | -0.20 | -0.81 | -15.57 |
| Average Basic Shares Outstanding | 5.31M | 8.00M | 3.71M | 1.16M | 120.00K |
| Average Diluted Shares Outstanding | 5.42M | 8.00M | 3.71M | 1.16M | 120.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |